Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_2
1
33%
Ph phase_3
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Active, not recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

active_not_recruiting267%
not_yet_recruiting133%

Recent Activity

2 active trials
Showing 3 of 3
active_not_recruitingphase_1

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

NCT05453903
active_not_recruitingphase_2

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

NCT03591510
not_yet_recruitingphase_3

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

NCT07223814

Clinical Trials (3)

Showing 3 of 3 trials
NCT05453903Phase 1

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Active Not Recruiting
NCT03591510Phase 2

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Active Not Recruiting
NCT07223814Phase 3

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3